Several factors contribute to the occurrence of disability in multiple sclerosis, but steps can be taken to prevent or delay its onset.
The nature of multiple sclerosis makes it unlikely to be accurately diagnosed upon first presentation.
We explore the role of metabolomics in the diagnosis and treatment of multiple sclerosis and other diseases.
The acceleration of telemedicine during the pandemic has allowed us to gain vast insights into what works and what does not.
Can an MS ”prodrome” be defined clinically? We discuss the work of researchers that attempts to answer this question.
We explore the role of ASOs in MS treatment today, and why combination therapy may produce better clinical outcomes.
In the management of any disease in which relapses are known to occur, it is important to identify the risk factors for their occurrence, as well as any other factors that might influence their severity. In this article, we will be assessing the risk factors for relapse in patients with neuromyelitis optica spectrum disorder (NMOSD)…
We examine how hypoxia drives inflammation in multiple sclerosis—and how the opposite can happen as well.
The blood-brain barrier is the guardian of the central nervous system, but its stubborn resistance to DMTs presents a unique problem to medical researchers.
Cell-based therapies could potentially replace disease modifying therapies as the preferred choice of multiple sclerosis medication.